Koen de Nijs

Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening

Iakovos Toumazis, Koen de Nijs, Pianpian Cao et al. · JAMA Oncology · 2021 · 62 citations · Full text

Medicine, Pharmacoeconomics, Preventive Medicine +15

Risk Model–Based Lung Cancer Screening

Iakovos Toumazis, Pianpian Cao, Koen de Nijs et al. · Annals of Internal Medicine · 2023 · 61 citations · Full text

Medicine, Health Promotion, Preventive Medicine +17

Assessing the impact of increasing lung screening eligibility by relaxing the maximum years‐since‐quit threshold: A simulation modeling study

Rafael Meza, Pianpian Cao, Koen de Nijs et al. · Cancer · 2023 · 22 citations · Full text

Medicine, Health Promotion, Preventive Medicine +14

Medical costs of lung cancer by stage, histology and first-line treatment modality in the Netherlands (2012–2021)

Koen de Nijs, Harry J. de Koning, Carlijn van der Aalst et al. · European Journal of Cancer · 2024 · 16 citations · Full text

Medicine, Oncology, Pharmacoeconomics +17

Cost‐effectiveness of risk‐based low‐dose computed tomography screening for lung cancer in Switzerland

Yuki Tomonaga, Koen de Nijs, Heiner C. Bucher et al. · International Journal of Cancer · 2023 · 14 citations · Full text

Medicine, Oncology, Pharmacoeconomics +17